RESULTS: In patients of group B, PaCO2 and FEV1 were significantly improved compared with baseline (P < 0.01, P < 0.05) after 1 year treatment. CAT scores markedly improved after 6 months treatment in two groups of COPD patients (P < 0.05, P < 0.01). CAT score was further improved in group B after 12 months therapy compared with 6 month therapy (P < 0.05). The ratio of CAT improvement after 6 months and 12 months were higher in group B compared with group A (P < 0.05, P < 0.01). There was no significant difference in the percentage of annual rates in acute exacerbations between two treatment groups. Compared with the normal control, no evidence showed bad effect of glycometabolism and bone metabolism in COPD patients. The incidence of pneumonia was similar in two treatment groups.